BMS-986142

Phase 2Small molecule

Bristol-Myers Squibb

BMS-986142 is one of 84 small molecule programs targeting Inflammatory Bowel Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory Bowel DiseaseActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

LupusActive, not recruiting

Inflammatory Bowel DiseasePhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

LupusPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actemra

Simponi

19 3

Remicade

OOrganon and Co

Preclinical

43 4

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 5

Ilaris

Novartis

Preclinical

3 6

Celexa

AbbVie

Preclinical

1 7

BMS-986142

Bristol-Myers Squibb

Phase 2

1 8

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 9

Cataflam

Rituxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics2 trials

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02257151·118 enrolled

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02762123·28 enrolled

Female1 trial

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02832180·25 enrolled

Metabolism1 trial

Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02880670·9 enrolled

Primary Sjögren's Syndrome1 trial

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02843659·45 enrolled

Rheumatoid Arthritis1 trial

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02638948·508 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for BMS-986142. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986142 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986142. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986142

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics2 trials

Female1 trial

Metabolism1 trial

Primary Sjögren's Syndrome1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News